Results 161 to 170 of about 3,690,081 (295)

Virtual or In‐Person: Does It Matter? Comparing Pain, Function, Quality of Life, Self‐Efficacy, and Physical Function Outcomes of Virtual, Hybrid, and In‐Person Education and Exercise Program Participants

open access: yesArthritis Care &Research, EarlyView.
Objective This study aimed to determine if program format (in‐person, virtual, or hybrid) results in differences in 3‐month outcomes of pain, function, quality of life, self‐efficacy, and chair stands in a hip/knee osteoarthritis‐management program. Methods A secondary analysis of the Good Life with osteoArthritis in Denmark (GLA:D) Canada database was
Jill Van Damme   +7 more
wiley   +1 more source

Low-Temperature Propane Activation and Mineralization over a Co3O4 Sub-nanometer Porous Sheet: Atomic-Level Insights

open access: yesJACS Au, 2023
Yanfei Jian   +8 more
doaj   +1 more source

Preferences for post‐traumatic osteoarthritis prevention strategies in individuals with anterior cruciate ligament injury

open access: yesArthritis Care &Research, Accepted Article.
Objectives There is growing interest in evaluating new strategies to delay or prevent post‐traumatic osteoarthritis (PTOA) in individuals who have sustained anterior cruciate ligament (ACL) injury. This study sought to determine characteristics of potential treatments that are acceptable to patients with ACL injury.
Kevin Kennedy   +9 more
wiley   +1 more source

Integrating multiple slack bus operations and metaheuristic techniques for power flow optimization. [PDF]

open access: yesSci Rep
Dahal S   +5 more
europepmc   +1 more source

Effectiveness and Safety of Baricitinib for Juvenile Idiopathic Arthritis–Associated Uveitis or Chronic Anterior Antinuclear Antibody–Positive Uveitis

open access: yesArthritis Care &Research, EarlyView.
Objective To evaluate the efficacy and safety of baricitinib in pediatric patients with active juvenile idiopathic arthritis–associated uveitis (JIA‐U) or chronic anterior antinuclear antibody–positive uveitis, who had an inadequate response to methotrexate (MTX) or biologic disease‐modifying antirheumatic drugs (bDMARDs).
Athimalaipet V. Ramanan   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy